Kusakari T, Kariya M, Mandai M, Tsuruta Y, Hamid A A, Fukuhara K, Nanbu K, Takakura K, Fujii S
Department of Gynecology and Obstetrics, Faculty of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-5807, Japan.
Br J Cancer. 2003 Dec 15;89(12):2293-8. doi: 10.1038/sj.bjc.6601423.
Ovarian cancer is believed to develop from the ovarian surface epithelium through the accumulation of aberrations of oncogenes and/or tumor suppressor genes. However, it is unclear how the gene abnormalities are involved in ovarian carcinogenesis. To elucidate the process, we transfected genes reported to show their abnormalities in human ovarian cancers into human ovarian surface epithelial cells. Immortalization of the cells was achieved by the transfection of SV40 large T antigen (LT) and human telomerase reverse transcriptase (hTERT); however, the resultant cells showed no tumorigenesis. Additional transfection of either c-erbB-2 or mutant Ha-ras into the immortalized cells showed the anchorage-independent growth and tumorigenesis in mice with the incidence of 50% and 40%, respectively. Histologically, all the tumours were undifferentiated. In association with the tumorigenesis, the cells expressing c-erbB-2 or mutant Ha-ras demonstrated increased vascular endothelial growth factor secretion under hypoxia and enhanced resistance to apoptosis compared with the immortalized cells. Collectively, the introduction of either c-erbB-2 or mutant Ha-ras in the cells, which were efficiently immortalized by the transfection of LT and hTERT, showed tumorigenicity, suggesting that c-erbB-2 or mutant Ha-ras genes might be involved in ovarian carcinogenesis.
卵巢癌被认为是由卵巢表面上皮细胞通过癌基因和/或肿瘤抑制基因的异常积累发展而来。然而,尚不清楚基因异常是如何参与卵巢癌发生的。为了阐明这一过程,我们将据报道在人类卵巢癌中显示异常的基因转染到人类卵巢表面上皮细胞中。通过转染SV40大T抗原(LT)和人类端粒酶逆转录酶(hTERT)实现细胞永生化;然而,所得细胞未显示出肿瘤发生。将c-erbB-2或突变型Ha-ras进一步转染到永生化细胞中,分别在50%和40%的小鼠中显示出不依赖贴壁生长和肿瘤发生。组织学上,所有肿瘤均为未分化型。与肿瘤发生相关,与永生化细胞相比,表达c-erbB-2或突变型Ha-ras的细胞在缺氧条件下表现出血管内皮生长因子分泌增加以及对凋亡的抗性增强。总体而言,在通过转染LT和hTERT有效永生化的细胞中引入c-erbB-2或突变型Ha-ras显示出致瘤性,表明c-erbB-2或突变型Ha-ras基因可能参与卵巢癌发生。